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Abstract
Epigenetic regulation was first studied in the 1970s and has quickly gained global interest. It
is involved at many different stages of mammalian cell development. The broad nature of
epigenetic regulation has led to it being referred to as an ‘all stage’ mechanism of regulation
as it is implicated in many developmental stages including embryonic development, ageing
and in cancer progression. The term ‘epigenetic’ refers to the alteration of gene expression
without changing the genomic sequence. Epigenetic regulation involves the main subtypes
of DNA methylation and histone modification, and microRNA expression. Epigenetic alter-
ation is used by mammalian cells to ‘turn-on and -off’ the gene expression. During embry-
onic development this process is used to induce cell apoptosis of genes that are no longer
useful. During cancer development, epigenetics works to repress tumour suppressor gene
expression and activate oncogene expression. The stability and sustainability for the detec-
tion of epigenetic markers make it an attractive area for biomarker and drug discovery. In
this book chapter we will discuss the key epigenetic processes involved in mammalian cell
development and disease progression, specifically in cancer.
Keywords: epigenetic, DNA methylation, histone modification, microRNA, tumour
suppressors, cell development
1. Introduction
1.1. Types of epigenetic regulation
The term ‘epigenetics’ describes the stable modifications of gene expression that occur at
different stages of cell development and proliferation [1]. Epigenetic modifications are an
essential component for human development and cell differentiation, but can also come about
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through random changes and external environmental influences. Different genetic makeups
produce different individuals, while the differentiation of organs and various diseases is
controlled by epigenetic signatures (Figure 1). Epigenetic modification can also be a mecha-
nisms used to protect bacterial or viral modification in the host cell that affect cellular function.
There are a number of epigenetic alterations that are required for cellular functions including:
DNA methylation and histone modification, and microRNA expression. Epigenetic alterations
influence cellular function by altering the protein levels without changing the genomic DNA
sequences. These post translational modifications are recognised by specific proteins that are
closely associated with DNA as a mediator that causes modifications [2]. The DNA methyla-
tion process was first discovered in the 1970s and was later recognised as a major contributor
to the stabilisation of gene expression [3].
1.1.1. DNA methylation and histone modification
DNA methylation is an essential process for the normal development of biological systems [4]
and its dysregulation has been associated with various pathologies including cancer [5].
Although DNA methylation is known to be integral to the development and is strongly
associated with disease, there is limited knowledge on the specifics of its changes during
cellular differentiation and its relation to histone methylation and chromatin modifications.
DNA methylation can alter the genome to supress gene expression in mammalian cells. It
occurs by the methylation of deocycytosine (dC) bases at the 50prime position of the cytosine
to create deoxymethylcytosine (dmC). The majority of dmC are located in CG dinucleotides
with approximately 80% of CG pairs being methylated. The majority of these CG pairs are
localised to CG-rich DNA regions termed CpG islands. An abundance of transcription factor
binding sites exist at CpG islands, which exist in the promoter regions for some genes. CpG
islands are present in the promoter regions of approximately half of all mammalian genes [6].
DNA methylation occurs at CG dinucleotides termed CpGs that are distributed globally in
80% of genomes in non-embryonic cells. CpGs sites located at short CpG regions generally
remain unmethylated at all times [7, 8]. The majority of CpG islands reside in the promoter
Figure 1. Top panel depicts various species, each with a unique genomic signature. Bottom, within the same individual
the differentiation of cell function is controlled by a cell specific epigenetic signature.
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region of a gene [9] and are also known to be associated with the transcriptional activity of Sp1
[10]. When CpG islands become methylated during mammalian cell development this can lead
to long-term silencing of the associated gene [11].
DNA methyltransferases (DNMT) are a family of enzymes consisting of members DNMT1,
DNMT3a and DNMT3b that mediate DNA methylation. These members have different and
integral roles to execute DNA methylation; DNMT1 is involved in the maintenance of methyl-
ation patterns while DNMT3a and DNMT3b are responsible for de novo methylation, that is,
methylating DNA that is previously unmethylated [12]. DNA methylation signatures are
developed during cell differentiation for the purpose of supressing genes with functions that
are unnecessary to the mature cell. This de novo methylation is carried out by DNMT3a and
DNMT3b [13]. After differentiation, DNMT1 replicates these methylation patterns in the pro-
cess of mitosis [12]. Unstimulated cells express small amounts of DNMT1, but following
mitogenic stimulation the enzyme is upregulated by a sequence of pathways including
MAPK/ERK and JNK [14]. DNMT1 is then able to maintain methylation patterns in the DNA
by producing symmetrically methylated sites in parent and daughter DNA strands. It accom-
plishes this by recognising hemi-methylated CG dinucleotides in parent DNA strands and
transferring methyl groups from S-adenosylmethione (SAM) to cytosine regions of the
unmethylated daughter strand [12]. Alternatively, de novo methylation rarely occurs during
this normal post-gastrulation development stage and is instead prevalent during processes
such as establishment of cell lines in vitro [15] and in cancer cells.
DNA methylation is an important process during development and researchers have shown
the deletion of de novo methylation enzyme DNMT1 in mouse embryonic stem cells led to
dramatic DNA hypomethylation [16]. DNMT3a and DNMT3b predominantly exert enzyme
activity during the oocyte stage and in early pre-implantation embryos [12]. DNMT3b is also
transcribed during zygotic gene activation (ZGA) and highly expressed by blastocysts that
acquire epiblast lineage. The absence (by deletion) of DNMT3b led to embryonic lethality and
the deletion of DNMT3a was partially viable during development [13]. There is a lower
requirement for DNMT3L in DNA methylation which is used predominantly during imprint-
ing control region (ICR) methylation in gametes [17]. However, it is a crucial activating
cofactor for DNMT3a [18]. DNMT2 differs structurally from other DNMTand does not present
with phenotype modification in knockout mice models which are referred to as a misnomer
and depicts methylation activity on RNA [19].
DNA methylation is predominantly found in cytosines of the CG dinucleotide in mammalian
cells; this modification is post-replicable. The extent of DNA methylation changes in an orches-
trated way during mammalian development, starting with a wave of demethylation during
cleavage, followed by genome-wide de novo methylation after implantation [20]. Demethylation
is an active process that strips the male genome off methylation within hours of fertilisation [21];
by contrast, the maternal genome is only passively demethylated during subsequent cleavage
divisions [22]. The extent of methylation in the genome of the gastrulating embryo is high owing
to de novo methylation, but it tends to decrease in specific tissues during differentiation [17]. De
novo methylation occurs rarely during normal post-gastrulation development but is seen fre-
quently during the establishment of cell lines in vitro [15] and in cancer.
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A variety of chromatin modifications can halt the initiation of transposable element (TE) tran-
scription in mammalian cells; modifications of histone tails, chromatin packaging alterations,
DNA methylation and condensation are all examples of this. Histone amino (N)-terminal tails
modification causes changes to protein factor binding and in turn relays information to tran-
scription factors. DNA methylation of histone H3 at lysine 9 (H3K9) occurs in nucleosomes, that
are associated with TE’s, leading to transcriptional repression and inactivation of chromatin [23].
Sometimes, mutations can occur in genes that are required for the repression of histone tail
modifications, subsequently leading to TE reactivation. A specific example occurred in mouse
embryonic stem (ES) cells where mutations of the histone H3K9 DNMT gene suppressor of
variegation 3–9 (Su(var)3–9) drove the upregulation of TE transcripts [23].
It is widely understood that histones, specifically H3 and H4, are methylated at lysine (Lys)
and arginine (Arg) sites. The predominant regions for Lys-specific methylation on histones
that have been catalogued in literature are: Lys9, Lys4, Lys36, Lys27, Lys79 on H3 and Ls20
located on H4 [24]. Additionally, Lys site methylation can occur by mono-, di-, or tri-
methylation. The differential manners of Lys residue methylation dictate the variety of func-
tional consequences of Lys methylation.
The pioneering study that uncovered the functions of H3 Lys-methylation determined that one
of the well-understood Su(var) genes encodes a histone methyltransferase (HMT). The
Drosophlia SU(Var)3–9 gene was discovered to have roles in transcriptional silencing associated
with heterochromatin [25]. The human homologue of this gene, Suv39H1, underwent bio-
chemical analysis and its protein was found to methylate histone H3 at Lys9 using its enzy-
matic functions [26]. Expanding on this, specific antibodies for methylation of H3 at different
sites revealed a pathway for heterochromatin formation [27]. An example of this occurs in
S. pombe, where heterochromatin formation is initiated by the deacetylation of histone H3 at Lys9
by a histone deacetylase (HDAC) complex that allows the methylation of this site by histone-
lysine N-methyltransferase (Clr4). The chromodomain of heterochromatin protein (HP1) can
then recognise and bind to this methylated Lys9 motif. This in vivo study demonstrated that
disruption to the Clr4 gene caused delocalisation of the HP1 homologue Swi6, depicting the
requirement of H3 methylation for HP1 and heterochromatin assembly [27]. Genetics studies in
S. pombe and Tetrahymena have illustrated that heterochromatin formation is dependent on genes
that code for elements of the RNA interference (RNAi) machinery [28]. Additionally, small RNAs
are thought to target histone-modifying activities at silenced regions [29].
Although the association of Lys4-methylated H3 with euchromatic regions is well established,
its role in transcriptional activation is not completely understood. Lys4-methylated H3 was
found to be directly bound to the yeast chromatin remodelling enzyme Isw1p [30]. Further
supporting their association with transcriptional sites, Lys4 methylated H3 was shown to
inhibit the binding of the HDAC complex NuRD (nucleosome remodelling and HDAC) to
chromatin in a mammalian system [31]. Together, these findings suggest that Lys4-methylated
H3 regions indirectly regulate transcription by maintaining promoter genomic regions in a
state that favours transcriptional activation.
HDACs drive the deacetylation of acetyl-L-lysine side chains in histones to repress transcrip-
tion by altering the conformation of chromatin [32]. To date, there are 18 known HDACs
including: class I HDACs [33]; class IIa HDACs [34]; class IIb HDACs [35]; class III HDAC
enzymes sirtuins [35]; and finally the only class IV enzyme HDAC11 [33]. To catalyse the
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deacetylation of histone groups, HDACs together with HDAC related deacetylases, must
switch a single metal ion at the metal ion binding site Mn2+B in arginase [36].
1.1.2. microRNA expression
Epigenetic mechanisms play a pivotal role in the regulation of gene expression that forms part
of the large complex network that regulates the functioning of eukaryotic cells. MicroRNAs
(miRNAs) are a class of small RNA molecules that post-transcriptionally repress gene expres-
sion through interaction with the three prime untranslated region/s (30-UTR) of target messen-
ger RNAs (mRNA)s [37]. miRNAs have a wide variety of functional roles in biological systems
that have been extensively studied but the mechanisms controlling their expression are not
well understood. In most cases, miRNA expression is initiated by transcription of the miRNA
gene by RNA polymerase II. Genes transcribed by RNA polymerase II are frequently regulated
by epigenetic mechanisms, so it is likely that DNA methylation regulates the expression of
miRNAs. The notion of DNA methylation-based regulation of miRNAs is further supported
by the tissue-specific or developmental-stage specific pattern of miRNA expression [38].
A specific study carried out to determine if DNA methylation can alter miRNA expression
was carried out using HCT116 colon cancer cells with knockout of DNMT. This model
illustrated that approximately 10% of miRNAs studied were regulated by DNAmethylation.
Furthermore, these miRNAs were shown to be tightly regulated by methylation as shown by
a high level of CpG site demethylation required to induce their re-expression. Treatment
with 5-aza-20-deoxycytidine (AZA) or induction of partial demethylation was unsuccessful
in upregulating these miRNAs. Collectively, these findings could be directly due to the
demethylation of CpG islands in the miRNA promoter sites or be explained instead by the
indirect epigenetic regulation of transcription factors acting on these miRNAs [39].
Many miRNAs with tumour suppressor functions have been shown to be silenced by hyper-
methylation in cancer [40]. miR-148a, miR-34b/c, miR-9-1, miR-9-2 and miR-9-3 were observed
to have specific CpG island hyper-methylation associated silencing in vitro and in vivo in
metastatic cancer cells. The metastatic carcinoma cell line SIHN-011B was hypermethylated
leading to the repression ofmiR-148a andmiR-34b/c. Transfection of SIHN-011Bwith expression
vectors containing the flanking regions of mature miR-148 andmiR-34b/c induced a reduction in
migration ability compared to controls in wound-healing assays. Tumour and metastasis forma-
tion assays in nude mice depicted a reduction in tumour growth over time following miRNA
transfection. These findings illustrate the tumour suppressor activity of these miRNAs, which
were found to be explicitly downregulated by CpG island hypermethylation in miRNA pro-
moter regions in these cell lines [41].
The epigenetic regulation of miRNAs is not solely limited to DNA methylation. Two separate
studies showed no change in miRNA expression following AZA treatment in lung or bladder
cancer cell lines. Combination treatments with a histone deacetylase inhibitor induced miRNA
upregulation [42]. To study the mechanisms leading to miRNA regulation more closely a
separate group compared the miRNA gene expression profile of a DNMT1 and DNMT3b
double knockout cell line model to its associated parental cell line HCT116. Their results
depicted notable alterations in miRNA expression in the double knockout model, strongly
suggesting that DNA methylation significantly regulates gene expression [39].
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2. Epigenetic regulations involvement mammalian cell function gene
silencing during development
DNA methylation is the most prevalent form of epigenetic alterations, the most studied and
therefore the remainder of this chapter will focus on this area. During mammalian cell devel-
opment, DNA methylation is an essential component to turn genes ‘on and off’ [13], however
this exact mechanism is still undefined. DNMTs cloning techniques [12] has led to the
improved understanding of how DNAmethylation proteins and methylation signals influence
mammalian cells. The DNA binding protein located on cytosines on the 50 position of the DNA
sequence contributes to the major ‘on and off’ gene mechanism of mammalian cells. DNA
methylation is a heritable trait through mammalian cell development, and these inherited
changes of methylation status prompted researchers to develop techniques to identify different
stages of cell development. DNA methylation has a multitude of roles in development, specif-
ically methylation of CpG-rich promoter regions and is responsible for the inactivation of the X
chromosome and to maintain its silencing. The roles of methylation do not stop with cellular
development, the normal functioning of DNA can be affected by methylation and is responsi-
ble for the development of human diseases including carcinogenesis. Epigenetic alterations can
occur in a mammalian system during different stages of development and can also be effected
by external stimuli as shown in Figure 2 that summarises the regulation of mammalian cells by
various epigenetic networks.
Different DNMTs are essential during different stages of vertebrate development and will con-
tribute to cell apoptosis in embryos and fibroblasts [43], but not in ES cells or cancer cells [44].
Figure 2. Mammalian cells react to external stimulus such as antigens and carcinogens. The generation of reactive oxygen
species (ROS) leading to the alteration of DNAmethyltransferase (DNMTs), histone deacetylase (HDACs) and microRNA
(miRNA) expression/processing at different stages, will lead to cell apoptosis or epigenetic alterations which allow cells to
progress to disease types. TF: transcription factor.
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The dysregulated activity of DNMTs results in the repression or activation of gene expression
[43] and transcriptional activation elements in diseased mammalian cells [45]. Additionally,
aberrant deletion of DNMT1 during brain development has been known to lead to perinatal
respiratory distress and malfunction of embryonic development [46]. DNA hypermethylation
causes gene silencing via binding of DNMTs to the genome which interferes with the activity
of transcription binding proteins that activate gene transcription [47].
2.1. DNA methylation and evaluation of mammalian cells
Genetic variation in individuals can influence phenotypic representation of age and lifespan [48].
However epigenetic and environmental factors also have significant roles in determining physio-
logical changes [49]. This is particularly exemplified by the increasing inherent epigenetic varia-
tion present in monozygotic twins with age [50]. DNA methylation status is altered in multiple
tissues and specific cell types with age, with the most frequent changes being age-dependent
while others remain unchanged with age [51]. Different tissues have specific DNA methylation
patterns that results in different cellular functions.
Genome-wide assays have provided a platform for discovering the effect of ageing during the
phenotypic alteration in liver cells and a study found that the level of visceral fat is involved in
cytosine methylation. This was the first investigation to show that ageing contributes to
changes in DNA methylation which is locus-specific in both liver and adipose tissues. These
changes appear to cause global hypermethylation in liver specific tissues in genetically identi-
cal rat models when exposed to the same environmental conditions throughout their life. This
hypermethylated pattern is usually accompanied by hypomethylation at the paired locus. Epi-
genomic dysregulation has a stable but reversible effect on the genomic sequence. The stability
and tissue specific potential of epigenetic marks highlights their potential as biomarkers for the
heterogenetic pathophysiology encountered during ageing. In most cases, these epigenetic
changes occur in genes that are involved in metabolism and metabolic dysregulation. There-
fore, epi-genomic dysregulation is a primary mediator for the pathogenesis of age-related
metabolic disease [52]. DNA methylation plays a major role during the ageing process that
contributes vastly to loss of tissue homeostasis, the decline of normal cellular functions and the
capacity for replication [53]. The accumulation of fat deposits with increasing age in the liver
can reduce the capacity of the liver to regenerate and function [54] which may lead to diseases
such as diabetes, dyslipidaemia and cardiovascular disease [55]. Ageing is a result of accumu-
lating genomic damage over time that is accompanied by physiological decline [56].
DNMT1 is responsible for the maintenance of DNA methylation levels and also acts as a
catalyst for methylation [57]. DNA methylation becomes more frequent when there is existing
methylation which ensures the self-perpetuation of methylation status. This process results in
de novo methylation extending from the already methylated regions to surrounding sequences
during ageing and cancer progression, leading to an overall reduction in global methylation as
methylation-specific enzymes are concentrated in these areas [58]. The direction and strength
of the correlation between age and methylation is dependent on the CpG island status of loci.
During ageing CpG island loci gain methylation and non-islanded CpGs become less methyl-
ated. Researchers have frequently shown that methylation status is increased within CpG
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islands with age [59, 60]. Tra et al. and Bjornsson et al. showed bi-modal age-related methyla-
tion in aged tissues vs. normal tissues using microarray. A direct comparison of the top 50
most age-related and normal methylation genomes show an overall decreased methylation
status in non-CpG island regions of normal samples [51]. They also indicated an inverse
correlation trend in other tissue types, where they found that although methylation occurs at
non-CpG island regions, there is a strong correlation between age and methylation at the CpG
island regions [61].
Studies have indicated that age-related methylation is a common mechanism of dysregulation
regardless of tissue specificity [62]. There is a reduction in the fidelity to maintain DNMTs
activity with ageing and this potentially results in the age-related reduction of methylation
[63]. On the other hand, age-related hypermethylation is a reflection of accumulating stochas-
tic methylation events over time [64]. However, these methylated CpGs in mammalian cells
may not have dramatic functional consequences due to the absence of pathologic phenotype
differences [65]. The accumulation of alterations without functional consequences should not
be considered biologically insignificant, because age-related alteration of the normal epi-
genome without changes in gene expression may confer a significantly increased risk to
pathologic phenotypes and altered gene expression or genomic instability [64]. For example,
the methylation of ‘non-functional’ CpG islands in promoter regions of an aged individual can
continue to accumulate methylation events (methylation spreading) and increase the chance of
methylation induced gene silencing in the future [64]. The increasing spread of methylation
can also affect gene expression of distant loci via silencing of important genomic regions, such
as enhancers resulting in progression to a diseased phenotype [66]. Fortunately, the aberrant
CpG methylation causing gene silencing on a single allele can be compensated by the comple-
mentary allele that is not methylated. Thus, the clusters of mono-allelic gene expression will
increase the risk of pathologic phenotype alteration, for example the loss of the 2nd functional
allele. As a result, it is necessary to study the potential of quantification of age and/or environ-
mental exposure that is associated with DNA methylation which can act as an indication of
disease risk [67].
Other DNA methylation mechanisms are involved in cellular ageing and provide a large area
of discovery, these include: endogenous hypomethylation and exogenous hypermethylation
[68]. Age-dependent decreases in DNA methylation, including possible endogenous changes
that alter gene expression or the function of DNMT and demethylases, as well as exogenous
factors like diet, drugs and UV may also result in gene expression alteration [69]. Endogenous
DNMT alteration can arise at different stages of cellular development from new-born, middle
aged, to elderly individuals. All of these factors may lead to gene overexpression and the
increase of ‘transcriptional noise’, however this is not fully understood in the mammalian
system. Exogenous agents that affect DNA methylation may affect cellular function in the
long-term [47]. Cells treated with demethylation agents can become re-methylated due to the
action of their DNAmethylation maintenance mechanisms which endure multiple insults with
accumulating age [70]. Dietary deficiencies in folate, choline, methionine, zinc and/or selenium
can result in alteration of DNA methylation status [71]. Folate and choline deficiency may
contribute to DNA hypomethylation in the liver that leads to liver cancer development [72].
Folate deficiency can also lead to an increase of homocysteine levels and promote degeneration
of neurons in Alzheimer’s and Parkinson’s disease [73].
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The mechanisms involved in hypermethylation of CpG islands with ageing are not well
understood. Wu et al., showed increased levels of DNMT1 leading to CpG island methylation
and phenotype changes in fibroblasts, suggesting the increased level of the protein contributed
to process of phenotypic modification. Under normal cellular development DNMT1 may
increase in response to DNA hypomethylation that is caused by drug intake and dietary
deficiencies which lead to increased DNA methylation and contributes to the DNA methyla-
tion balance of the cell.
2.2. DNA methylation and disease development
Germline and somatic mutations are mainly the result of cytosine methylation during cancer
development [74]. Abnormal promoter methylation of the regulatory genes can lead to gene
silencing and is an important mechanism of cancer progression [75]. Rare diseases such as
immunodeficiency, centromeric region instability, facial anomalies syndrome (ICF) [13] and
mental retardation in young girls (Rett Syndrome) are the potential consequence of abnormal
methylation alteration [76]. For example, ICF patients are found to be have a mutated
DNMT3b gene that leads to the downregulation of satellite DNA methylation and chromo-
somal de-condensation. Methylation binding domains (MBDs, MeCP2) were found to be
aberrantly methylated in Rett Syndrome patients, resulting in the interruption of the methyla-
tion signal [76]. Together this suggests methylation is not completed after embryonic develop-
ment, requires maintenance and is essential in mammalian cells. Alternatively, the increasing
methylation of mammalian cells may contribute to the risk of cancer development. Therefore,
the balance of methylation is essential in maintaining healthy cellular function.
Many studies have indicated that the imbalance of DNA methylation occurs in the disease
mechanism which leads to the discovery of pharmacological agents that reverse epigenetic
abnormalities [77]. The interaction of DNA methylation and histone modification machinery
were further investigated and proved to be an important contribution that led to disease
development. Another group of epigenetic alterations caused by small RNAs also play a major
role at different disease stages that could also be exploited to monitor treatment results [78].
2.3. DNA methylation and cancer development
DNA methylation and cancer development was first studied in the 1980s, showing DNA
hypomethylation in their normal counterparts of cancer cells [79]. The loss of DNA methyla-
tion in the repetitive regions of the genome was referred to as hypomethylation which led to
genomic instability and is a hallmark of tumour cells [80]. Hypomethylation can also lead to
over-expression of oncogenes that contributes to cancer progression [81]. Transcriptional inter-
ference describes the reactivation of transposon promoters via demethylation that contributes
to aberrant gene regulation in cancers [82]. Down-regulation of DNAmethylation occurs at the
early stages of cancer and correlates with disease progression and metastatic potential in many
cancer types [81]. The melanoma antigen (MAGE) family of cancer genes are a gene-specific
hypomethylation in cancer cells that encodes tumour antigens of unknown function that are
frequently demethylated and re-expressed in cancer [83]. Specific genes that are hypomethylated
in specific types of cancer include: S100 calcium binding protein A4 (S100A4) upregulated in
colon cancer [84], serine protease inhibitor gene SERPINB5 (also known as maspin) in gastric
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cancer [85] and the putative oncogene γ-synuclein (SNCG) in breast and ovarian cancers [86].
Global hypomethylation that occurs at early stages of tumorigenesis may be protected by
genomic instability and further genetic changes. However, gene-specific hypomethylation could
allow tumour cell adaptation to their local environment and promote metastasis. Research on
genome-wide demethylation in cancer cells has been largely overshadowed by studies of gene-
specific hypermethylation events, which occur concomitantly with the hypomethylation events
discussed above. In cancer cells, aberrant hypermethylation usually occurs at CpG islands that
are mostly unmethylated in normal somatic cells [87]. Histone deacetylation leads to changes in
chromatic structure that effectively silence transcription. In a subset of tumour types that are
referred to as CpG island-methylator phenotypes, there was a 3–5 fold increase in aberrant
methylation [88]. Most of the involved genes were regulators of cell-cycle, tumour cell invasion,
DNA repair, chromatic remodelling, cell signalling, transcription and apoptosis. Additionally
these genes are known to be aberrantly hypermethylated and silenced inmost cancers, favouring
cancer cell growth and increasing their genetic instability causing them to metastasize. In the
case of colon cancer, aberrant hypermethylation is detectable in the earliest precursor lesion,
indicating DNA hypermethylation is an early, detectable event during colon cancer development
and can be used as a biomarker [89].
Cancer can be described as a disease of ageing, Issa et al., reported global (repeat element)
hypomethylation and promoter hypermethylation of cancer cells are also found in normal
tissues with ageing [58]. Other studies have described the age-related methylation in normal
human prostate and colon tissues that contain CpG island bearing genes [90]. The alteration of
DNA methylation is age-related but also tissue-dependent. The process of DNA methylation
associated with ageing and promoter CpG methylation is complex. CpG islands are known to
contribute to gene silencing in cancer cells. Gene silencing of retinoic acid receptor- β (RAR β)
51 is an example of de novo methylation of the CpG island that causes leukaemia to develop in
humans [91]. During cancer development, interactions between DNMTs and HDACs may
facilitate de novo methylation to maintain permanent methylation of tumour suppressor genes
that are already down-regulated [92].
2.4. DNA methylation, biomarkers, treatment and monitoring of disease
Promoter hypermethylation of DNA can be used as biomarkers for the detection of different
cancerous cells when compared with methylation status of ‘normal-healthy’ cells. There is a
growing trend to develop DNA methylation based biomarkers for cancer diagnosis. This
area of development is attractive to researchers because of the stable and sustainable nature
of detection (even in circulation). Aberrant DNA methylation can also be used as a bio-
marker for malignant transformation. The development of a methylation-specific PCR tech-
nique in 1996 by Herman et al., became popular soon after their first publication [93]. It
offers a quick, easy, non-radioactive and sensitive way to detect hypermethylated CpG
regions of tumour suppressor genes and can detect unmethylated CpG regions in ‘normal-
healthy’ cells. Recently, the new droplet digital PCR technology and next generation
sequencing has moved methylation detection in clinical samples a step forward which is
sensitive enough to look at the traced methylation status of tumour suppressor genes in
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circulation. The advantage of this detection technology is built on the basis of the following:
positive PCR signals are not masked by the contamination of normal cells, promoter
hypermethylation can occur at an early stage of cancer which allows early diagnosis and all
tumours have one or more loci that contain hypermethylated tumour suppressor genes. The
development of detection techniques also allowed promoter hypermethylation to be identi-
fied using bronchoalveolar lavages [94], lymph nodes [95], stool and sputum [96] to screen
methylation of tumour suppressors. The screening of promoter hypermethylation in serum
DNA from non-small cell lung cancer also opens the avenue for researchers to further develop
this technology for diagnosis [97]. Septin 9 (Sept9) was the first FDA approved DNA methyla-
tion marker that utilised non-invasive serum samples from patients [98]; MLH1 is used for colon
cancer diagnosis [99] and O6-methylguanine-DNA-methyltransferase (MGMT1) is used for
brain cancer [100] diagnosis in the clinic.
The process of methylating dmC in cancer is complicated as malignancies have different
origins; it can either be direct or indirect influence by oncogenes or as part of cancer cell
adaptation to external stress response, environmental factors and exposure to therapeutic
genes and others [101, 102]. The distribution of dmC during cancer development will allow
cancer cells to abject their phenotypes, adapt to different tissue microenvironments and also
become resistant to therapeutic drugs [103]. Cancer associated upregulation of dmC at pro-
moters or enhancers of a genome can also cause tumour suppressor genes to become silenced
[104]. The commonly silenced tumour suppressor genes in most cancers CDKN2A, RB and
MLH1 are associated with aggressive cancer types and a poor prognosis [104]. DNA methyl-
ation can also be used to detect silenced genes involved in immune recognition or modulate a
response to chemotherapy, resulting in disruption of immune surveillance that induced che-
motherapy resistance [105]. However, these epigenetic alterations are reversible and it is
possible to reverse aberrant methylation with DNMT inhibitor (DNMTi) or a demethylating
agent (i.e. decitabine) which allows the restoration of the genomic functions [67]. The advan-
tages of these drugs are their ability to reprogram cancer cells to undergo terminal differenti-
ation, induce chemosensitisation, loss of self-renewal properties or become visible to immune
system. DNMTi and decitabine can also be used to induce anti-tumour response by induction
of endogenous stimulation of interferon response pathways [106].
The multifaceted and easy detection of dmC highlights its great potential to be used as a
biomarker with utilisation of the improved detection methods of methylated DNA using
modified DNA fragments. dmC biomarkers have now become a convincing predictor of
clinical outcomes and are able to predict response to DNMTi in the clinic. They can also be
used to classify cancer into biological and clinically distinct disease subtypes, providing
guidance for chemotherapeutic drug selection. The use of tumour suppressor gene CDKN2A
methylation status has shown to be prognostically significant in many cancer types [107]. In
leukaemia patients, clinicians use the panel 16 methylated gene panel as a biomarker for
detection using microarray and showed that differentially methylated regions (DMTs) are
useful to predict outcomes of patients and their clinical variability. This dmC detection
technology has been developed further as biomarkers and is validated in acute myeloid
leukaemia (AML) patients [108]. The DMRs can also be used to predict response of patients
with chronic myelomonocytic leukaemia to DNMTi [109]. Hypermethylation and silencing
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of SMAD1 was useful as a predictive biomarker for chemotherapy resistance in patients with
high-risk diffuse large B-cell lymphoma (DLBCL) [110]. SMAD1 silencing also showed con-
tribution to chemotherapy resistance that can be reversed by DNMTis in patients [110].
Results were favourable for the use of DNMTi in patients diagnosed with high-risk DLBCL,
in combination with decitabine before rituximab in combination of cyclophosphamide,
doxorubine, vincristine and prednisone chemo-immunotherapy. MGMT which is a DNA
repair enzyme has also proved to be useful as a predictive marker for alkylating agent
response [111].
3. Epigenetic regulation and drug discovery
Other epigenetic factors are useful for drug discovery, such as acetylation, methylation and
phosphorylation, ubiquitination, sumoylation and ADP-ribosylation [112, 113]. A list of these
agents is summarised in Table 1a and Table 1b [114, 115]. Vincent Alfrey et al., suggested
modifications of acetylation have functional roles in modulating transcription and it was later
established by others that the process of chromatin and post-translational modification of
epigenetic regulation may be interrupting DNA [116]. HDAC are a family of enzymes respon-
sible for chromatin modification. Aberrant regulation of this family of genes has been studied
in many cancers and used in pharmacological target discovery. The inhibition of chromatin-
modification enzymes is a key process to modulate transcription in eukaryotic cells which led
to the development of novel pharmacologic agent discovery. HDAC inhibitor (HDACi),
vorinostat, was the FDA approved treatment for patients with advanced refractory cutaneous
T-cell lymphoma. This provides evidence that HDACi is a useful therapeutic treatment, how-
ever the different subtypes of HDAC should be considered to achieve promising therapeutic
interventions. The discovery of both HDACi and DNMTi provide options for clinical treatment
alone or possible use with other agents in combination therapies for the treatment of various
diseases that are related to epigenetic abnormalities [117].
4. Conclusion
Epigenetic regulation is an attractive area of research; it provides a broad spectrum of
discovery as it is involved in almost all developmental processes of the mammalian cell from
Name DNMT inhibitor Clinical status Treatment
Decitabine 5-AZA-CdR FDA and the European
Medicines Agency
Myelodysplastic syndromes (MDS), acute myeloid leukaemia
(AML), and chronic myelomonocytic leukaemia (CMML)
5-AZA Nucleoside
analogues
azacitidine
FDA and the European
Medicines Agency
Myelodysplastic syndromes (MDS), acute myeloid leukaemia
(AML), and chronic myelomonocytic leukaemia (CMML)
Table 1a. DNMT inhibitors.
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early fertilisation, implantation, embryonic development, ageing and carcinogenesis.
As evolutionary stages require different types of epigenetic signature, the various epigenetic
patterns have been exploited in biomarker discovery to identify distinctive/unique stages
of disease (typically cancer) development. Although DNA methylation is the most studied
area of epigenetics, there are not many markers that are currently used as standard clinical
diagnostic markers. Due to the stability of DNA in cells and in circulation we believe that
with the development of new technologies and methods, DNA methylation biomarkers
Class HDAC
inhibitor
Target
HDAC Class
Clinical status
Hydroxamic acids SAHA pan Approved for cutaneous T-cell lymphoma
Belinostat pan Approved for peripheral T-cell lymphoma
Panabiostat pan Approved for multiple myeloma
Givinostat pan Phase II clinical trials—relapsed leukaemia and multiple
myeloma
Resminostat pan Phase I and II clinical trials—hepatocellular carcinoma
Abexinostat pan Phase II clinical trial—B-cell lymphoma
Quisinostat pan Phase I clinical trial—multiple myeloma
Rocilinostat II Phase I clinical trial—multiple myeloma
Practinostat I, II and IV Phase II clinical trial—prostate cancer
CHR-3996 I Phase I clinical trial—advanced/metastatic solid tumours
refractory to standard therapy
Valproic acid I, IIa Approved for epilepsia, bipolar disorders and migraine, phase II
clinical trials—several studies
Short chain fatty
acids
Butyric acid I, II Phase II clinical trials—several studies
Phenylbutyric
acid
I, II Phase I clinical trials—several studies
Entinostat I Phase II clinical trials—breast cancer, Hodgkin’s lymphoma, non-
small cell lung cancer, phase III clinical trial—hormone receptor
positive breast cancer
Benzamides Tacedinaline I Phase III clinical trial—non-small cell lung cancer and pancreatic
cancer
4SC202 I Phase I clinical trial—advanced haematological malignancies
Mocetinostat I, IV Phase II clinical trials—Hodgkin’s lymphoma
Romidepsin I Approved for cutaneous T-cell lymphoma
Cyclic tetrapeptides Nicotinamide All class III Phase III clinical trial—laryngeal cancer
Sirtuins inhibitors EX-527 SIRT 1 and 2 Cancer preclinical, phase I and II clinical trials—Huntington
disease, glaucoma
Table 1b. HDAC inhibitors.
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have the potential to become a favourable clinical diagnostic marker. Further research is
required in this field to ensure the widespread application of DNA methylation markers in
the clinical setting.
Abbreviations
30-UTR three prime untranslated region
AML acute myeloid leukaemia
Arg arginine
AZA 5-aza-20-deoxycytidine
Clr4 histone-lysine N-methyltransferase
dC deocycytosin
DLBCL diffuse large B-cell lymphoma
dmC deoxymethylcytosine
DMTs differentially methylated regions
DNMT DNA methyltransferases
ES embryonic stem
H3K9 histone H3 at lysine 9
HDAC histone deacetylase
HMT histone methyltransferase
HP1 heterochromatin protein
ICF facial anomalies syndrome
ICR imprinting control region
Lys lysine
MBD Methylation binding domains
MGMT1 O6-methylguanine-DNA-methyltransferase
miRNAs MicroRNAs
mRNA messenger RNA
NuRD nucleosome remodelling
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RAR β retinoic acid receptor- β
RNAi RNA interference
ROS reactive oxygen species
S100A4 S100 calcium binding protein A4
SAM S-adenosylmethione
TE transposable element
TF transcription factor
ZGA zygotic gene activation
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